---
title: "DC 7725 - Myelodysplastic syndromes:"
diagnostic_code: "7725"
body_system: "Hemic and Lymphatic Systems"
cfr_section: "§ 4.117"
canonical: "https://veteranai.co/va-rating-schedule/hemic-and-lymphatic/7725-myelodysplastic-syndromes"
source: "https://www.ecfr.gov/current/title-38/section-4.117"
updated: "2026-07-21T21:12:20.741343Z"
---

# DC 7725 - Myelodysplastic syndromes:

Rated under § 4.117. Body system: Hemic and Lymphatic Systems.

## Rating criteria

| Rating | Criteria |
| --- | --- |
| 100% | Requiring peripheral blood or bone marrow stem cell transplant; or requiring chemotherapy |
| 60% | Requiring 4 or more blood or platelet transfusions per 12-month period; or infections requiring hospitalization 3 or more times per 12-month period |
| 30% | Requiring at least 1 but no more than 3 blood or platelet transfusions per 12-month period; infections requiring hospitalization at least 1 but no more than 2 times per 12-month period; or requiring biologic therapy on an ongoing basis or erythropoiesis stimulating agent (ESA) for 12 weeks or less per 12-month period |

## Notes

- Note (1): If the condition progresses to leukemia, evaluate as leukemia under diagnostic code 7703
- Note (2): A 100 percent evaluation shall be assigned as of the date of hospital admission for peripheral blood or bone marrow stem cell transplant, or during the period of treatment with chemotherapy, and shall continue with a mandatory VA examination six months following hospital discharge or, in the case of chemotherapy treatment, six months after completion of treatment. Any reduction in evaluation based upon that or any subsequent examination shall be subject to the provisions of § 3.105(e) of this chapter. If there has been no recurrence, residuals will be rated under the appropriate diagnostic codes

# Myelodysplastic Syndromes (VA Diagnostic Code 7725)

## Understanding Your VA Disability Rating for Myelodysplastic Syndromes

Myelodysplastic syndromes are conditions affecting the **Hemic and Lymphatic Systems**. The VA rates this condition under **Diagnostic Code 7725**, found in **38 CFR § 4.117**.

---

## Available Rating Levels

The VA assigns a disability rating based on the treatment your condition requires and its effects over a 12-month period. Here are the rating levels for Myelodysplastic Syndromes:

### 100% Rating
Assigned when the condition requires **peripheral blood or bone marrow stem cell transplant**, or requires **chemotherapy**.

### 60% Rating
Assigned when the condition requires:
- **4 or more** blood or platelet transfusions per 12-month period; **or**
- Infections requiring hospitalization **3 or more times** per 12-month period

### 30% Rating
Assigned when the condition requires:
- **At least 1 but no more than 3** blood or platelet transfusions per 12-month period; **or**
- Infections requiring hospitalization **at least 1 but no more than 2 times** per 12-month period; **or**
- **Biologic therapy on an ongoing basis**, or an erythropoiesis stimulating agent (ESA) for **12 weeks or less** per 12-month period

---

## What the VA Looks For

When evaluating Myelodysplastic Syndromes, the VA considers the type and frequency of treatment your condition requires, including:

- Whether you require a stem cell transplant or chemotherapy
- The number of blood or platelet transfusions needed over a 12-month period
- How often infections require hospitalization over a 12-month period
- Whether ongoing biologic therapy or an erythropoiesis stimulating agent (ESA) is required

---

## Important Notes

**Progression to Leukemia:** If the condition progresses to leukemia, it is evaluated as leukemia under Diagnostic Code 7703.

**Treatment-Related 100% Evaluation:** A 100 percent evaluation is assigned as of the date of hospital admission for a peripheral blood or bone marrow stem cell transplant, or during the period of treatment with chemotherapy. This evaluation continues, with a mandatory VA examination scheduled six months following hospital discharge or, in the case of chemotherapy, six months after completion of treatment. Any reduction in evaluation based on that or a subsequent examination is subject to the provisions of § 3.105(e). If there has been no recurrence, any residuals will be rated under the appropriate diagnostic codes.

Source: https://www.ecfr.gov/current/title-38/section-4.117